Biocon Biologics secures Canada market entry date for YESAFILI
This agreement paves the way for the introduction of YESAFILI into the Canadian market
This agreement paves the way for the introduction of YESAFILI into the Canadian market
Launch of Indian public health standards for Ayush healthcare facilities
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
ICMR’s budgetary allowance has increased by 4-fold in the past 10 years, showcasing our commitment towards Health Research
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra
Cipla completes transfer of Generics Business Undertaking
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Subscribe To Our Newsletter & Stay Updated